This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Indolent lymphoid malignancies are a group of heterogeneous disorders that share certain clinical and biological characteristics. These common elements include relatively slow growth, initial sensitivity to chemotherapy, unrelenting relapse after chemotherapy, and the inevitable development of resistance to cytotoxic chemotherapy. While multiple chemotherapeutic regimens have been developed over the last several decades, there has been no improvement in overall survival demonstrated for this group of patients during this same time period. With the possible exception of stem cell transplantation, patients with other than very localized disease treatable with radiation are considered to be incurable.The hypothesis and specific aims are: 1) To determine the safety of IDEC-Y2B8 when administered to patients with 35% marrow involvement with lymphoma after they have been treated with rituximab. 2) To determine the maximum tolerated dose of IDEC-Y2B8 when administered with rituximab in vivo purging and autologous stem cell rescue. 3) To obtain correlative laboratory data of in vivo purging with rituximab in patients with #5% marrow involvement.
Showing the most recent 10 out of 1014 publications
